QNTM SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 26, 2026

20-F/A

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]

Mar 31, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 28, 2025

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Apr 1, 2024

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 31, 2023

20-F

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Mar 31, 2022

News

TYPE

HEADLINE

FILED AT

6-K

Quantum BioPharma Files Supplement to Management Information Circular for Fractional Share Treatment and MVS Voting Power Threshold

Nov 5, 2026

6-K

Quantum BioPharma Announces Court Consolidation of Lawsuit Against CIBC and RBC and Appointment of Lead Counsel

Oct 8, 2026

6-K

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Oct 6, 2026

6-K

Quantum BioPharma Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin as CEO and Prepares for Stock Exchange Listing

Sep 24, 2026

6-K

Quantum BioPharma Announces Corporate Updates, Warrant Cancellation, Option Grant, and Closing of Fourth Debenture Tranche

Sep 17, 2026

6-K

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Sep 17, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

December 2025 ATM | Offering amount: $17,243,174 | Amount sold to date: $0 | Float: 3,582,377

Dec 22, 2025

424B5

October 2025 ATM | Amount sold to date: $1,326,147 | Float: 3,387,857

Oct 31, 2025

424B5

ATM | Offering amount: $2,235,601 | Amount sold to date: $8,918,631

Aug 26, 2024

424B5

ATM | Offering amount: $11,154,232 | Amount sold to date: $0 | Float: 33,131,383

Feb 16, 2024

Registrations

TYPE

HEADLINE

FILED AT

F-3

SHELF | Offering amount: $50,000,000.00 | Amount sold to date: $0.00 EFFECTIVE

Dec 22, 2023

Registration

Jul 19, 2023

F-10

US$100,000,000- -WITHDRAWN

Apr 2, 2021

FWP

Registration

Jul 31, 2020

F-10/A

Total debt of $1,900,000 less $150,000 converted to Class B Shares during Q2 2020

Jun 16, 2020

F-10

C$100,000,000

Feb 28, 2020

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

AdvisorShares Trust (Filed by)

Oct 5, 2026

SCHEDULE 13G

AdvisorShares Trust (Filed by)

Jul 8, 2026

SCHEDULE 13G/A

Malone Wealth Ventures LLC (Filed by)

Feb 3, 2026

SCHEDULE 13G/A

Malone Wealth Ventures LLC (Filed by)

Sep 4, 2025

SCHEDULE 13G/A

Malone Wealth Ventures LLC (Filed by)

Jul 18, 2025

SCHEDULE 13G/A

Malone Wealth Ventures LLC (Filed by)

Jul 10, 2025

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 5, 2024

CORRESP

Form CORRESP - Correspondence

Dec 29, 2023

LETTER

Form UPLOAD - SEC-generated letter

Dec 29, 2023

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Feb 11, 2021

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Oct 16, 2020

SUPPL

Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)]

Jul 31, 2020

Quantum BioPharma Ltd. QNTM · SEC Filings